rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2026-141-148rsp-3910Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСистемная красная волчанка и острые нарушения мозгового кровообращенияSystemic lupus erythematosus and acute cerebral circulatory disordershttps://orcid.org/0000-0002-7465-0677ПизоваН. В.PizovaN. V.

Пизова Наталия Вячеславовна

150000, Ярославль, ул. Революционная, 5

Nataliia V. Pizova

150000, Yaroslavl, Revolyutsionnaya str., 5

pizova@yandex.ruhttps://orcid.org/0000-0002-0522-675XПизовА. В.PizovA. V.

150000, Ярославль, ул. Республиканская, 108/1

Aleksandr V. Pizov

150000, Yaroslavl, Respublikanskaya str., 108/1

ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical UniversityRussian FederationФГБОУ ВО «Ярославский государственный педагогический университет им. К.Д. Ушинского»РоссияYaroslavl State Pedagogical University named after K.D. UshinskyRussian Federation202601052026642141148Copyright © Пизова Н.В., Пизов А.В., 20262026Пизова Н.В., Пизов А.В.Pizova N.V., Pizov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3910

Системная красная волчанка (СКВ) – системное аутоиммунное заболевание, характеризующееся широким спектром клинических проявлений. Сердечно-сосудистые заболевания являются признанным осложнением СКВ. Острые нарушения мозгового кровообращения у пациентов с СКВ могут протекать в виде ишемического или геморрагического инсульта, а также по типу церебрального венозного тромбоза. Патофизиологические механизмы в зависимости от типа острого нарушения мозгового кровообращения имеют свои особенности. При СКВ ишемический инсульт протекает по нескольким различным механизмам, включая кардиоэмболию, стеноз крупных артерий неатеросклеротической или атеросклеротической этиологии, артериальную диссекцию, гиперкоагуляционные состояния и другие. Наряду с основными общепопуляционными факторами риска поражение почек при СКВ может увеличивать риск развития инсульта. Инсульт является одной из причин смертельного исхода у пациентов с СКВ.

Systemic lupus erythematosus is a systemic autoimmune disease characterized by a wide spectrum of clinical manifestations. Cardiovascular disease is a common complication of systemic lupus erythematosus. Acute cerebral circulatory disorders in patients with systemic lupus erythematosus may present as ischemic or hemorrhagic stroke, or as cerebral venous thrombosis. The pathophysiologic mechanisms depending on the type of acute cerebral circulation disorder are different and have their own peculiarities. In systemic lupus erythematosus, ischemic stroke occurs by several different mechanisms, including cardioembolism, stenosis of large arteries of nonatherosclerotic or atherosclerotic etiology, arterial dissection, hypercoagulable states, and others. Along with major population-wide risk factors for stroke, kidney damage in systemic lupus erythematosus may increase the risk of stroke. Stroke is one of the causes of death among patients with systemic lupus erythematosus.

системная красная волчанкаишемический инсультгеморрагический инсультцеребральный венозный тромбознефротический синдромsystemic lupus erythematosusischemic strokehemorrhagic strokecerebral venous thrombosisnephrotic syndromeИсследование не имело спонсорской поддержкиReferencesНасонов ЕЛ, Решетняк ТМ, Соловьев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023;95(5):365-374. doi: 10.26442/00403660.2023.05.202246Nasonov EL, Reshetnyak TM, Solovyev SK, Popkova TV. Systemic lupus erythematosus and antiphospholipid syndrome: Past, present, future. Terapevticheskii arkhiv. 2023;95(5):365-374 (In Russ.). doi: 10.26442/00403660.2023.05.202246Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and meta-analysis. Int Immunopharmacol. 2021;94:107466. doi: 10.1016/j.intimp.2021.107466Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and meta-analysis. Int Immunopharmacol. 2021;94:107466. doi: 10.1016/j.intimp.2021.107466Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6(2):e001247. doi: 10.1136/rmdo-pen-2020-001247Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6(2):e001247. doi: 10.1136/rmdo-pen-2020-001247Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). Ann Rheum Dis. 2019;78(6):802-806. doi: 10.1136/annrheumdis-2018-214802Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). Ann Rheum Dis. 2019;78(6):802-806. doi: 10.1136/annrheumdis-2018-214802Al-Ewaidat OA, Naffaa MM. Deciphering mechanisms, prevention strategies, management plans, medications, and research techniques for strokes in systemic lupus erythematosus. Medicines (Basel). 2024;11(7):15. doi: 10.3390/medicines11070015Al-Ewaidat OA, Naffaa MM. Deciphering mechanisms, prevention strategies, management plans, medications, and research techniques for strokes in systemic lupus erythematosus. Medicines (Basel). 2024;11(7):15. doi: 10.3390/medicines11070015Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, Guerrero-Torres L, Flores-Silva F, Chiquete E, et al. Stroke in systemic lupus erythematosus: Epidemiology, mechanism, and long-term outcome. Lupus. 2020;29(5):437-445. doi: 10.1177/0961203320908947Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, Guerrero-Torres L, Flores-Silva F, Chiquete E, et al. Stroke in systemic lupus erythematosus: Epidemiology, mechanism, and long-term outcome. Lupus. 2020;29(5):437-445. doi: 10.1177/0961203320908947Huang JA, Lin CH, Wu MJ, Chen YH, Chang KC, Hou CW. Ten-year follow-up investigation of stroke risk in systemic lupus erythematosus. Stroke Vasc Neurol. 2024;9(1):1-7. doi: 10.1136/svn-2022-001499Huang JA, Lin CH, Wu MJ, Chen YH, Chang KC, Hou CW. Ten-year follow-up investigation of stroke risk in systemic lupus erythematosus. Stroke Vasc Neurol. 2024;9(1):1-7. doi: 10.1136/svn-2022-001499Nikolopoulos D, Fanouriakis A, Boumpas DT. Cerebrovascular events in systemic lupus erythematosus: Diagnosis and management. Mediterr J Rheumatol. 2019;30(1):7-15. doi: 10.31138/mjr.30.1.7Nikolopoulos D, Fanouriakis A, Boumpas DT. Cerebrovascular events in systemic lupus erythematosus: Diagnosis and management. Mediterr J Rheumatol. 2019;30(1):7-15. doi: 10.31138/mjr.30.1.7Aryal A, Aryal A, Kshetri D, Karki S, Khadka S. Recurrent left ischemic stroke in a patient with systemic lupus erythematosus: A case report. Clin Case Rep. 2023;11(11):e8192. doi: 10.1002/ccr3.8192Aryal A, Aryal A, Kshetri D, Karki S, Khadka S. Recurrent left ischemic stroke in a patient with systemic lupus erythematosus: A case report. Clin Case Rep. 2023;11(11):e8192. doi: 10.1002/ccr3.8192Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: Prevalence, associations, and evolution. Am J Med. 2007;120(7):636-642. doi: 10.1016/j.amjmed.2007.01.024Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: Prevalence, associations, and evolution. Am J Med. 2007;120(7):636-642. doi: 10.1016/j.amjmed.2007.01.024Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973983. doi: 10.1016/j.jcmg.2013.04.012Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973983. doi: 10.1016/j.jcmg.2013.04.012Kitano T, Hirano T, Okazaki S, Itotagawa E, Yagita Y, Morita Y, et al. Heterogeneity of stroke in patients with systemic lupus erythematosus. Intern Med. 2022;61(20):3045-3052. doi: 10.2169/internalmedicine.9228-21Kitano T, Hirano T, Okazaki S, Itotagawa E, Yagita Y, Morita Y, et al. Heterogeneity of stroke in patients with systemic lupus erythematosus. Intern Med. 2022;61(20):3045-3052. doi: 10.2169/internalmedicine.9228-21Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38(2):281-285. doi: 10.1161/01.STR.0000254476.05620.14Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38(2):281-285. doi: 10.1161/01.STR.0000254476.05620.14Su L, Qi Z, Guan S, Wei L, Zhao Y. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study. Front Immunol. 2022;13:978910. doi: 10.3389/fimmu.2022.978910Su L, Qi Z, Guan S, Wei L, Zhao Y. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study. Front Immunol. 2022;13:978910. doi: 10.3389/fimmu.2022.978910Ioannidis S, Mavridis M, Mitsias PD. Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature. eNeurologicalSci. 2018;13:26-30. doi: 10.1016/j.ensci.2018.11.001Ioannidis S, Mavridis M, Mitsias PD. Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature. eNeurologicalSci. 2018;13:26-30. doi: 10.1016/j.ensci.2018.11.001Habes YMN, Ahmaro M, Dwikat Y, Jobran AWM, Abunejma FM, Abdulrazzak M. Stroke as an unusual initial presentation of ‘malignant’ middle cerebral artery infarction involvement in systemic lupus erythematosus. Ann Med Surg (Lond). 2023;86(1):517-521. doi: 10.1097/MS9.0000000000001502Habes YMN, Ahmaro M, Dwikat Y, Jobran AWM, Abunejma FM, Abdulrazzak M. Stroke as an unusual initial presentation of ‘malignant’ middle cerebral artery infarction involvement in systemic lupus erythematosus. Ann Med Surg (Lond). 2023;86(1):517-521. doi: 10.1097/MS9.0000000000001502Chung MS, Byun JS, Yim Y. A case report of pontine infarction as an initial manifestation of systemic lupus erythematosus: Diagnostic clues from MRI and digital subtraction angiography. Taehan Yongsang Uihakhoe Chi. 2021;82(5):1281-1286. doi: 10.3348/jksr.2021.0039Chung MS, Byun JS, Yim Y. A case report of pontine infarction as an initial manifestation of systemic lupus erythematosus: Diagnostic clues from MRI and digital subtraction angiography. Taehan Yongsang Uihakhoe Chi. 2021;82(5):1281-1286. doi: 10.3348/jksr.2021.0039Costa P, Silva AR, Carones A, Teixeira S, Coimbra P. Stroke and multiorgan failure as the initial manifestations of lupus. Cureus. 2024;16(4):e57980. doi: 10.7759/cureus.57980Costa P, Silva AR, Carones A, Teixeira S, Coimbra P. Stroke and multiorgan failure as the initial manifestations of lupus. Cureus. 2024;16(4):e57980. doi: 10.7759/cureus.57980Mohammadian R, Tarighatnia A, Naghibi M, Koleini E, Nader ND. Vertebrobasilar artery stroke as the heralding sign of systemic lupus erythematosus. J Stroke Cerebrovasc Dis. 2018;27(5):e80-e85. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.003Mohammadian R, Tarighatnia A, Naghibi M, Koleini E, Nader ND. Vertebrobasilar artery stroke as the heralding sign of systemic lupus erythematosus. J Stroke Cerebrovasc Dis. 2018;27(5):e80-e85. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.003Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407-2415. doi: 10.1056/NEJMoa035611Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407-2415. doi: 10.1056/NEJMoa035611Blohorn A, Guegan-Massardier E, Triquenot A, Onnient Y, Tron F, Borg JY, et al. Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: A descriptive study of 139 patients. Cerebrovasc Dis. 2002;13(3):156-162. doi: 10.1159/000047769Blohorn A, Guegan-Massardier E, Triquenot A, Onnient Y, Tron F, Borg JY, et al. Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: A descriptive study of 139 patients. Cerebrovasc Dis. 2002;13(3):156-162. doi: 10.1159/000047769Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004;63(1):31-35. doi: 10.1136/ard.2003.007740Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004;63(1):31-35. doi: 10.1136/ard.2003.007740Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62(11):1071-1077. doi: 10.1136/ard.62.11.1071Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62(11):1071-1077. doi: 10.1136/ard.62.11.1071Romero-Diaz J, Garcia-Sosa I, Sanchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol. 2009;36:68-75. doi: 10.3899/jrheum.071244Romero-Diaz J, Garcia-Sosa I, Sanchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol. 2009;36:68-75. doi: 10.3899/jrheum.071244Candelario-Jalil E, Dijkhuizen RM, Magnus T. Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities. Stroke. 2022;53:1473-1486. doi: 10.1161/STROKEAHA.122.036946Candelario-Jalil E, Dijkhuizen RM, Magnus T. Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities. Stroke. 2022;53:1473-1486. doi: 10.1161/STROKEAHA.122.036946Wiseman SJ, Bastin ME, Jardine CL, Barclay G, Hamilton IF, Sandeman E, et al. Cerebral small vessel disease burden is increased in systemic lupus erythematosus. Stroke. 2016;47(11):2722-2728. doi: 10.1161/STROKEAHA.116.014330Wiseman SJ, Bastin ME, Jardine CL, Barclay G, Hamilton IF, Sandeman E, et al. Cerebral small vessel disease burden is increased in systemic lupus erythematosus. Stroke. 2016;47(11):2722-2728. doi: 10.1161/STROKEAHA.116.014330Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-218. doi: 10.1177/0961203310395803Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-218. doi: 10.1177/0961203310395803Li J, Pan Z, Liu H, Ding F, Shu Q, Li X. Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. Medicine (Baltimore). 2018;97(27):e11356. doi: 10.1097/MD.0000000000011356Li J, Pan Z, Liu H, Ding F, Shu Q, Li X. Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. Medicine (Baltimore). 2018;97(27):e11356. doi: 10.1097/MD.0000000000011356Gao N, Wang ZL, Li MT, Han SM, Dang YQ, Zhang FC, et al. Clinical characteristics and risk factors of intracranial hemorrhage in systemic lupus erythematosus. Lupus. 2013;22(5):453-460. doi: 10.1177/0961203313477226Gao N, Wang ZL, Li MT, Han SM, Dang YQ, Zhang FC, et al. Clinical characteristics and risk factors of intracranial hemorrhage in systemic lupus erythematosus. Lupus. 2013;22(5):453-460. doi: 10.1177/0961203313477226Arinuma Y, Kikuchi H, Aramaki K, Kyogoku M, Hirohat S. Histopathological analysis of cerebral hemorrhage in systemic lupus erythematosus complicated with antiphospholipid syndrome. Mod Rheumatol. 2011;21(5):509-513. doi: 10.1007/s10165-011-0420-0Arinuma Y, Kikuchi H, Aramaki K, Kyogoku M, Hirohat S. Histopathological analysis of cerebral hemorrhage in systemic lupus erythematosus complicated with antiphospholipid syndrome. Mod Rheumatol. 2011;21(5):509-513. doi: 10.1007/s10165-011-0420-0Qayyum W, Khan S, Iqbal MS, Khan MF, Yousafzai ZA, Afaq S. Massive haemorrhage: An unusual presentation of systemic lupus erythematosus. JRSM Open. 2021;12(11):20542704211062041Qayyum W, Khan S, Iqbal MS, Khan MF, Yousafzai ZA, Afaq S. Massive haemorrhage: An unusual presentation of systemic lupus erythematosus. JRSM Open. 2021;12(11):20542704211062041Cugno M, Gualtierotti R, Tedeschi A, Meroni PL. Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy. Autoimmun Rev. 2014;13(1):40-48. doi: 10.1016/j.autrev.2013.08.001Cugno M, Gualtierotti R, Tedeschi A, Meroni PL. Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy. Autoimmun Rev. 2014;13(1):40-48. doi: 10.1016/j.autrev.2013.08.001Wang L, Chen H, Zhang Y, Liu W, Zheng W, Zhang X, et al. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: A single-centre experience in China. J Immunol Res. 2015;2015:540738. doi: 10.1155/2015/540738Wang L, Chen H, Zhang Y, Liu W, Zheng W, Zhang X, et al. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: A single-centre experience in China. J Immunol Res. 2015;2015:540738. doi: 10.1155/2015/540738Duman T, Demirci S, Uluduz D, Kozak HH, Demir S, Mısırlı CH, et al.; VENOST Study Group. Cerebral venous sinus thrombosis as a rare complication of systemic lupus erythematosus: Subgroup analysis of the VENOST study. J Stroke Cerebrovasc Dis. 2019;28(12):104372. doi: 10.1016/j.jstrokecerebrovasdis.2019.104372Duman T, Demirci S, Uluduz D, Kozak HH, Demir S, Mısırlı CH, et al.; VENOST Study Group. Cerebral venous sinus thrombosis as a rare complication of systemic lupus erythematosus: Subgroup analysis of the VENOST study. J Stroke Cerebrovasc Dis. 2019;28(12):104372. doi: 10.1016/j.jstrokecerebrovasdis.2019.104372Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-2337. doi: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-iEsdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-2337. doi: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-iGigante A, Barbano B, Liberatori M, Sardo L, Gasperini ML, Rosato E, et al. Nephrotic syndrome and stroke. Int J Immunopathol Pharmacol. 2013;26(3):769-772. doi: 10.1177/039463201302600322Gigante A, Barbano B, Liberatori M, Sardo L, Gasperini ML, Rosato E, et al. Nephrotic syndrome and stroke. Int J Immunopathol Pharmacol. 2013;26(3):769-772. doi: 10.1177/039463201302600322Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. Circulation. 2008;117(2):224-230. doi: 10.1161/CIRCULATIONAHA.107.716951Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. Circulation. 2008;117(2):224-230. doi: 10.1161/CIRCULATIONAHA.107.716951Huang WY, Chang CW, Chen KH, Chang CH, Wu HC, Chang KH. Characteristics of acute ischemic stroke in patients with Nephrotic syndrome. Ren Fail. 2023;45(2):2284214. doi: 10.1080/0886022X.2023.2284214Huang WY, Chang CW, Chen KH, Chang CH, Wu HC, Chang KH. Characteristics of acute ischemic stroke in patients with Nephrotic syndrome. Ren Fail. 2023;45(2):2284214. doi: 10.1080/0886022X.2023.2284214Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, et al. Chronic kidney disease and cerebrovascular disease: Consensus and guidance from a KDIGO controversies conference. Stroke. 2021;52(7):e328-e346. doi: 10.1161/STROKEAHA.120.029680Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, et al. Chronic kidney disease and cerebrovascular disease: Consensus and guidance from a KDIGO controversies conference. Stroke. 2021;52(7):e328-e346. doi: 10.1161/STROKEAHA.120.029680Huang WY, Chang CW, Chen CM, Chen KH, Chang CH, Wu HC, et al. Characteristics of ischemic stroke and intracranial hemorrhage in patients with nephrotic syndrome. BMC Nephrol. 2021;22(1):213. doi: 10.1186/s12882-021-02415-wHuang WY, Chang CW, Chen CM, Chen KH, Chang CH, Wu HC, et al. Characteristics of ischemic stroke and intracranial hemorrhage in patients with nephrotic syndrome. BMC Nephrol. 2021;22(1):213. doi: 10.1186/s12882-021-02415-wTsoi LK, Mok CC, Man BL, Fu YP. Imaging pattern and outcome of stroke in patients with systemic lupus erythematosus: A casecontrol study. J Rheumatol. 2021;48:533-540. doi: 10.3899/jrheum.200664Tsoi LK, Mok CC, Man BL, Fu YP. Imaging pattern and outcome of stroke in patients with systemic lupus erythematosus: A casecontrol study. J Rheumatol. 2021;48:533-540. doi: 10.3899/jrheum.200664Mejia-Vilet JM, Turner-Stokes T, Houssiau F, Rovin BH. Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment. Best Pract Res Clin Rheumatol. 2023;37(4):101925. doi: 10.1016/j.berh.2023.101925Mejia-Vilet JM, Turner-Stokes T, Houssiau F, Rovin BH. Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment. Best Pract Res Clin Rheumatol. 2023;37(4):101925. doi: 10.1016/j.berh.2023.101925Wu D, Han M, Lee S. Risk of acute stroke young patients with new-onset lupus nephritis: A case series (P9-5.028). Neurol J. 2023;100. doi: 10.1212/WNL.0000000000204219Wu D, Han M, Lee S. Risk of acute stroke young patients with new-onset lupus nephritis: A case series (P9-5.028). Neurol J. 2023;100. doi: 10.1212/WNL.0000000000204219Lee MA, Hwang BW, Lee DK, Lee CJ, Kim JH, Ahn SH. Acute stroke caused by large vessel vasculitis in a patient with systemic lupus erythematosus. J Neurosonol Neuroimaging. 2022;14:51-54. doi: 10.31728/jnn.2022.00112Lee MA, Hwang BW, Lee DK, Lee CJ, Kim JH, Ahn SH. Acute stroke caused by large vessel vasculitis in a patient with systemic lupus erythematosus. J Neurosonol Neuroimaging. 2022;14:51-54. doi: 10.31728/jnn.2022.00112Gaspar P, Sciascia S, Tektonidou MG. Epidemiology of antiphospholipid syndrome: Macroand microvascular manifestations. Rheumatology (Oxford). 2024;63(SI):I24-I36. doi: 10.1093/rheumatology/kead571Gaspar P, Sciascia S, Tektonidou MG. Epidemiology of antiphospholipid syndrome: Macroand microvascular manifestations. Rheumatology (Oxford). 2024;63(SI):I24-I36. doi: 10.1093/rheumatology/kead571Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al.; ACR/EULAR APS Classification Criteria Collaborators. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. doi: 10.1136/ard-2023-224609Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al.; ACR/EULAR APS Classification Criteria Collaborators. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. doi: 10.1136/ard-2023-224609Bertoletti L, Benhamou Y, Béjot Y, Marechaux S, Cheggour S, Aleil B, et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Rev. 2018;32(4):272-279. doi: 10.1016/j.blre.2018.01.002Bertoletti L, Benhamou Y, Béjot Y, Marechaux S, Cheggour S, Aleil B, et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Rev. 2018;32(4):272-279. doi: 10.1016/j.blre.2018.01.002Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971. doi: 10.3389/fimmu.2018.02971Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971. doi: 10.3389/fimmu.2018.02971Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346(10):752-763. doi: 10.1056/NEJMra002974Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346(10):752-763. doi: 10.1056/NEJMra002974Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med. 1987;106:524-531. doi: 10.7326/0003-4819-106-4-524Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med. 1987;106:524-531. doi: 10.7326/0003-4819-106-4-524Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(10):1726-1732. doi: 10.1136/ard.2010.148502Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(10):1726-1732. doi: 10.1136/ard.2010.148502Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, HernandezJuarez J. The pathophysiology of the antiphospholipid syndrome: A perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022:28:10760296221088576. doi: 10.1177/10760296221088576Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, HernandezJuarez J. The pathophysiology of the antiphospholipid syndrome: A perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022:28:10760296221088576. doi: 10.1177/10760296221088576Leal Rato M, Bandeira M, Romão VC, Aguiar de Sousa D. Neurologic manifestations of the antiphospholipid syndrome – an update. Curr Neurol Neurosci Rep. 2021;21(8):41. doi: 10.1007/s11910-021-01124-zLeal Rato M, Bandeira M, Romão VC, Aguiar de Sousa D. Neurologic manifestations of the antiphospholipid syndrome – an update. Curr Neurol Neurosci Rep. 2021;21(8):41. doi: 10.1007/s11910-021-01124-zMendes GNN, Morais ABCG, Gioia LC, Jacquin G, Poppe AY, Soga FH, et al. Neurovascular complications of antiphospholipid syndrome: A narrative review. Arq Neuropsiquiatr. 2024;82(12):1-7. doi: 10.1055/s-0044-1793932Mendes GNN, Morais ABCG, Gioia LC, Jacquin G, Poppe AY, Soga FH, et al. Neurovascular complications of antiphospholipid syndrome: A narrative review. Arq Neuropsiquiatr. 2024;82(12):1-7. doi: 10.1055/s-0044-1793932Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, et al. A Panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(4):209-220. doi: 10.1002/acr2.11223Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, et al. A Panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(4):209-220. doi: 10.1002/acr2.11223Suszek D, Popławska M, Prośniak J, Siemieniec K, Przeniosło K, Wallach W, et al. A novel approach to cardiovascular events in patients with systemic lupus erythematosus: Risk factor assessment and treatment analysis. Rheumatol Int. 2025;45(6):139. doi: 10.1007/s00296-025-05894-4Suszek D, Popławska M, Prośniak J, Siemieniec K, Przeniosło K, Wallach W, et al. A novel approach to cardiovascular events in patients with systemic lupus erythematosus: Risk factor assessment and treatment analysis. Rheumatol Int. 2025;45(6):139. doi: 10.1007/s00296-025-05894-4Choi MY, Guan H, Yoshida K, Paudel M, Kargere BA, Li D, et al. Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2024;67:152468. doi: 10.1016/j.semarthrit.2024.152468Choi MY, Guan H, Yoshida K, Paudel M, Kargere BA, Li D, et al. Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2024;67:152468. doi: 10.1016/j.semarthrit.2024.152468Lai CH, Hsieh CY, Barnado A, Huang LC, Chen SC, Tsai LM, et al. Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: A population-based study. Rheumatology (Oxford). 2020;59(6):1355-1363. doi: 10.1093/ rheumatology/kez456Lai CH, Hsieh CY, Barnado A, Huang LC, Chen SC, Tsai LM, et al. Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: A population-based study. Rheumatology (Oxford). 2020;59(6):1355-1363. doi: 10.1093/ rheumatology/kez456Rossides M, Simard JF, Svenungsson E, von Euler M, Arkema EV. Mortality and functionality after stroke in patients with systemic lupus erythematosus. J Rheumatol. 2017;44(11):15901596. doi: 10.3899/jrheum.170241Rossides M, Simard JF, Svenungsson E, von Euler M, Arkema EV. Mortality and functionality after stroke in patients with systemic lupus erythematosus. J Rheumatol. 2017;44(11):15901596. doi: 10.3899/jrheum.170241Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus – a retrospective cohort study. Neuropsychiatr Dis Treat. 2014:10:1635-1643. doi: 10.2147/NDT.S64323Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus – a retrospective cohort study. Neuropsychiatr Dis Treat. 2014:10:1635-1643. doi: 10.2147/NDT.S64323Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005;64(12):2102-2107. doi: 10.1212/01.WNL.0000165959.98370.D5Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005;64(12):2102-2107. doi: 10.1212/01.WNL.0000165959.98370.D5Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, et al.; Systemic Lupus International Collaborating Clinics. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008;59(5):721-729. doi: 10.1002/art.23566Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, et al.; Systemic Lupus International Collaborating Clinics. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008;59(5):721-729. doi: 10.1002/art.23566Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al.; Systemic Lupus International Collaborating Clinics (SLICC). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69(3):529-535. doi: 10.1136/ard.2008.106351Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al.; Systemic Lupus International Collaborating Clinics (SLICC). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69(3):529-535. doi: 10.1136/ard.2008.106351Wang IK, Muo CH, Chang YC, Liang CC, Lin SY, Chang CT, et al. Risks, subtypes, and hospitalization costs of stroke among patients with systemic lupus erythematosus: A retrospective cohort study in Taiwan. J Rheumatol. 2012;39(8):1611-1618. doi: 10.3899/jrheum.111510Wang IK, Muo CH, Chang YC, Liang CC, Lin SY, Chang CT, et al. Risks, subtypes, and hospitalization costs of stroke among patients with systemic lupus erythematosus: A retrospective cohort study in Taiwan. J Rheumatol. 2012;39(8):1611-1618. doi: 10.3899/jrheum.111510Holmqvist M, Simard JF, Asplund K, Arkema EV. Stroke in systemic lupus erythematosus: A meta-analysis of population-based cohort studies. RMD Open. 2015;1:e000168. doi: 10.1136/rmdopen-2015-000168Holmqvist M, Simard JF, Asplund K, Arkema EV. Stroke in systemic lupus erythematosus: A meta-analysis of population-based cohort studies. RMD Open. 2015;1:e000168. doi: 10.1136/rmdopen-2015-000168Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: A systematic review and meta-analysis. Stroke. 2016;47:943-950. doi: 10.1161/STROKEAHA.115.012052Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: A systematic review and meta-analysis. Stroke. 2016;47:943-950. doi: 10.1161/STROKEAHA.115.012052Gu MM, Wang XP, Cheng QY, Zhao YL, Zhang TP, Li BZ, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest. 2019;48(5):505-520. doi: 10.1080/08820139.2019.1567534Gu MM, Wang XP, Cheng QY, Zhao YL, Zhang TP, Li BZ, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest. 2019;48(5):505-520. doi: 10.1080/08820139.2019.1567534Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016;3(1):e000143. doi: 10.1136/lupus-2015-000143Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016;3(1):e000143. doi: 10.1136/lupus-2015-000143Arkema EV, Svenungsson E, Von Euler M, Sjowall C, Simard JF. Stroke in systemic lupus erythematosus: A Swedish populationbased cohort study. Ann Rheum Dis. 2017;76:1544-1549. doi: 10.1136/annrheumdis-2016-210973Arkema EV, Svenungsson E, Von Euler M, Sjowall C, Simard JF. Stroke in systemic lupus erythematosus: A Swedish populationbased cohort study. Ann Rheum Dis. 2017;76:1544-1549. doi: 10.1136/annrheumdis-2016-210973Avina-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general population-based study. Arthritis Care Res. 2017;69:849-856. doi: 10.1002/acr.23018Avina-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general population-based study. Arthritis Care Res. 2017;69:849-856. doi: 10.1002/acr.23018Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Cerebrovascular events in systemic lupus erythematosus: Results from an international inception cohort study. Arthritis Care Res (Hoboken). 2018;70(10):1478-1487. doi: 10.1002/acr.23509Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Cerebrovascular events in systemic lupus erythematosus: Results from an international inception cohort study. Arthritis Care Res (Hoboken). 2018;70(10):1478-1487. doi: 10.1002/acr.23509Chang KC, Lin CH, Chen PL, Wu YH, Hou CW, Huang JA. Severe lupus flare is associated with a much higher risk of stroke among patients with SLE. Int J Stroke. 2023;118:957-964. doi: 10.1177/17474930231174227Chang KC, Lin CH, Chen PL, Wu YH, Hou CW, Huang JA. Severe lupus flare is associated with a much higher risk of stroke among patients with SLE. Int J Stroke. 2023;118:957-964. doi: 10.1177/17474930231174227Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheum-dis-2021-221733Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheum-dis-2021-221733Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Tektonidou MG, Andreoli L, Limper M. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296-1304. doi: 10.1136/annrheumdis-2019-215213Tektonidou MG, Andreoli L, Limper M. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296-1304. doi: 10.1136/annrheumdis-2019-215213Khairani CD, Bejjani A, Piazza G. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: Meta-analysis of randomized trials. J Am Coll Cardiol. 2023;81(1):16-30. doi: 10.1016/j.jacc.2022.10.008Khairani CD, Bejjani A, Piazza G. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: Meta-analysis of randomized trials. J Am Coll Cardiol. 2023;81(1):16-30. doi: 10.1016/j.jacc.2022.10.008Liu D, Li X, Zhang Y, Kwong JS, Li L, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:1685-1695. doi: 10.2147/DDDT.S166893Liu D, Li X, Zhang Y, Kwong JS, Li L, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:1685-1695. doi: 10.2147/DDDT.S166893Pawlak-Buś K, Leszczyński P. Hydroxychloroquine as an important immunomodulator: A novel insight into an old drug. Pol Arch Intern Med. 2024;134(1):16656. doi: 10.20452/pamw.16656Pawlak-Buś K, Leszczyński P. Hydroxychloroquine as an important immunomodulator: A novel insight into an old drug. Pol Arch Intern Med. 2024;134(1):16656. doi: 10.20452/pamw.16656

The authors declare that there are no conflicts of interest present.